180 Life Sciences Net debt/EBITDA
Was ist das Net debt/EBITDA von 180 Life Sciences?
Net debt/EBITDA von 180 Life Sciences Corp. ist 0.23
Was ist die Definition von Net debt/EBITDA?
The net debt to earnings before interest, taxes, depreciation, and amortization (Net debt/EBITDA) ratio measures financial leverage and the company’s ability to pay off its debt. It shows how long it would take the company to pay off all its debt with operations at the current level.
The net debt to EBITDA ratio is calculated as Net debt divided by EBITDA. It is similar to the debt to EBITDA ratio, but cash and cash equivalents are subtracted in net debt.
Net debt = short-term debt + long-term debt - cash and cash equivalents
EBITDA = net income + interest expense + taxes + depreciation + amortization
Lower debt debt to EBITDA ratio indicates the company is not heavily indebted and should be able to repay its obligations. Alternatively, higher ratio indicated the company is excessively indebted. The ratio varies between industries as different industries have different capital requirements. Usually, the ratio should be compared to a benchmark or an industry average to determine the company’s credit risk. Generally, a net debt to EBITDA ratio above 4 or 5 is considered high.
Net debt/EBITDA von Unternehmen in Health Care Sektor auf NASDAQ im Vergleich zu 180 Life Sciences
Was macht 180 Life Sciences?
180 Life Sciences Corp., a clinical-stage biotechnology company, engages in the development of novel drugs for unmet medical needs in chronic pain, inflammation, inflammatory diseases, and fibrosis. Its product development platforms in Phase IIb/III clinical trials include Fibrosis and anti-tumour necrosis factor (Anti-TNF) platform, which focuses on fibrosis and Anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which are man-made derivatives of CBD; and a7nAChR platform, which focuses on alpha 7 nicotinic acetylcholine receptor. The company was incorporated in 2016 and is headquartered in Palo Alto, California.
Unternehmen mit net debt/ebitda ähnlich 180 Life Sciences
- Kapston Facilities Management hat Net debt/EBITDA von 0.22
- EOG Resources hat Net debt/EBITDA von 0.23
- Aptorum hat Net debt/EBITDA von 0.23
- Agenus Inc hat Net debt/EBITDA von 0.23
- Biolife Solutions Inc hat Net debt/EBITDA von 0.23
- Infinity Logistics hat Net debt/EBITDA von 0.23
- 180 Life Sciences hat Net debt/EBITDA von 0.23
- First Bancorp hat Net debt/EBITDA von 0.24
- Flexiroam hat Net debt/EBITDA von 0.24
- Trxade Health Inc hat Net debt/EBITDA von 0.24
- Mkango Resources hat Net debt/EBITDA von 0.24
- Ausmon Resources hat Net debt/EBITDA von 0.24
- Elmo Software hat Net debt/EBITDA von 0.24